What is the 13F Pro Quality Score for SILO?

13F Pro ranks Silo Pharma, Inc. (SILO) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View SILO's current score at https://13fpro.ai/research/SILO (free sign-up required for the full ranking).

Where does 13F Pro source SILO data?

All Silo Pharma, Inc. fundamentals and ownership data come directly from SEC EDGAR. Silo Pharma, Inc. files with the SEC under CIK 1514183. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is SILO in?

Silo Pharma, Inc. (SILO) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is SILO research updated on 13F Pro?

SILO's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Silo Pharma, Inc.(SILO)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1514183 SILO stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.1M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

SILO Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Silo Pharma, Inc. (SILO), a Healthcare sector company. SILO is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.1m in revenue. Based on the latest XBRL financial filings (Q1 2026), Silo Pharma, Inc. reports quarterly revenue of $18.0K, net income of $-1.6M, free cash flow of $-822.6K. Top institutional holders of SILO by reported 13-F value include AdvisorShares Investments, GEODE CAPITAL MANAGEMENT,, SUSQUEHANNA INTERNATIONAL GROUP, LLP, based on the most recent SEC filings. SILO trades on the Nasdaq exchange and files with the SEC under CIK 1514183. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SILO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Silo Pharma, Inc. directly from SEC EDGAR.

Revenue

Q1 2026

$18.0K

Net Income

Q1 2026

$-1.6M

Free Cash Flow

Q1 2026

$-822.6K

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+0.0% YoY

$72.1KFY 2025

FY18 —FY22 $72.1KFY23 $72.1KFY25 $72.1K

Net Income

-14.2% YoY

$-4.2MFY 2025

FY18 $-969.5KFY22 $-3.9MFY23 $-3.7MFY25 $-4.2M

Operating Income

-11.0% YoY

$-4.3MFY 2025

FY18 $-594.2KFY22 $-3.6MFY23 $-3.9MFY25 $-4.3M

EPS (Diluted)

+58.3% YoY

$-0.50FY 2025

FY18 $-0.02FY22 —FY23 $-1.20FY25 $-0.50

Total Assets

-1.8% YoY

$7.6MFY 2025

FY18 $855.4KFY22 $11.6MFY23 $7.7MFY25 $7.6M

Op. Cash Flow

-44.6% YoY

$-4.7MFY 2025

FY18 $272.6KFY22 $-3.5MFY23 $-3.2MFY25 $-4.7M

Metric	FY 2025	FY 2023	FY 2022	FY 2018	FY 2016	FY 2013
Revenue	$72.1K +0.0%	$72.1K +0.0%	$72.1K	—	—	—
Net Income	$-4.2M -14.2%	$-3.7M +5.3%	$-3.9M -303.2%	$-969.5K	—	$-1.2M
Operating Income	$-4.3M -11.0%	$-3.9M -6.3%	$-3.6M -510.5%	$-594.2K	—	—
EPS (Diluted)	$-0.50 +58.3%	$-1.20	—	$-0.02	—	—
Total Assets	$7.6M -1.8%	$7.7M -33.5%	$11.6M +1261.1%	$855.4K	—	$2.2M
Operating Cash Flow	$-4.7M -44.6%	$-3.2M +7.8%	$-3.5M -1382.9%	$272.6K	—	$-181.6K

AI Insight: SILO Financial Trends

Silo remains pre-revenue with consistent quarterly losses of $1–2M and equity eroding toward zero.

• Revenue remains at $0M across all eight quarters; no commercial traction evident.

• Operating cash burn stable at $1–2M per quarter; Q1 2026 matches historical run rate.

• Equity declined from $7M (Q3 2024) to $6M (Q1 2026); cumulative losses eroding balance sheet.

⚠ Equity approaching critical threshold; continued $1–2M quarterly losses unsustainable without capital raise.

⚠ No pipeline milestones, clinical data, or revenue inflection signaled in available financials.

AI Insight: SILO Ratio Trends

Silo Pharma remains deeply unprofitable with deteriorating returns across all metrics through Q1 2026.

• ROE swung from -55.9% in Q4 2025 to -116.0% in Q1 2026, signaling acute shareholder value destruction.

• ROA declined to -93.9% in Q1 2026 from -46.4% in Q4 2025, reflecting worsening asset utilization.

• TTM ROIC stands at -84.2%, indicating sustained negative returns on invested capital.

⚠ Q1 2026 marks the sharpest ROE deterioration in the nine-quarter window; monitor burn rate sustainability.

⚠ Operating and net profit margins unavailable; unable to assess operational efficiency trends.

Get alerted when SILO's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Silo Pharma, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of SILO

AdvisorShares Investments LLC
$238.8K663,965 sh
GEODE CAPITAL MANAGEMENT, LLC
$64.8K180,031 sh
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$22.6K62,795 sh
JANE STREET GROUP, LLC
$16.1K44,763 sh
CITADEL ADVISORS LLC
$7.7K21,448 sh
XTX Topco Ltd
$6.1K17,083 sh
TWO SIGMA SECURITIES, LLC
$5.2K14,503 sh
VANGUARD FIDUCIARY TRUST CO
$4.7K13,100 sh
LPL Financial LLC
$4.5K12,534 sh
STATE STREET CORP
$4.5K12,500 sh

Fund	Value	Shares
AdvisorShares Investments LLC	$238.8K	663,965
GEODE CAPITAL MANAGEMENT, LLC	$64.8K	180,031
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$22.6K	62,795
JANE STREET GROUP, LLC	$16.1K	44,763
CITADEL ADVISORS LLC	$7.7K	21,448
XTX Topco Ltd	$6.1K	17,083
TWO SIGMA SECURITIES, LLC	$5.2K	14,503
VANGUARD FIDUCIARY TRUST CO	$4.7K	13,100
LPL Financial LLC	$4.5K	12,534
STATE STREET CORP	$4.5K	12,500

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put SILO on your watchlist

Track score changes the day Silo Pharma, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is SILO a good stock to buy?

13F Pro's AI-powered analysis of Silo Pharma, Inc. (SILO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SILO are available on the SILO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own SILO?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SILO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Silo Pharma, Inc.'s investment landscape.